Rank #1535RVMD

Revolution Medicines, Inc.

$102.74

2.96% (Daily)

Market Cap

$19.86B

Revenue

$N/A

Rank by MCap

#1535

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Mark A. Goldsmith M.D., Ph.D.

Headquarters

Redwood City, CA

Employees

809

About Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. I...